In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Zogenix, Inc.. Trade Record

NASDAQ:ZGNX Zogenix, Inc. stock gains 20.38% Exit Mar 6, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart ZGNX Jan 30, 2019, priceSeries
About Zogenix, Inc.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The company's lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
97.48
Entry Date
Jan 30, 2019
Entry Price
42.45
Sell Date
Mar 6, 2019
Sell Price
51.10
Net Gain
20.38%
Hold Time
24 Trading Days